173,369 research outputs found
The Merck index.
No full text1952-1960: "An encyclopedia for chemists, pharmacists, physicians, and members of allied professions."Published: Whitehouse Station, NJ, Editor: 1976- , M. Windholz."An encyclopedia of chemicals, drugs, and biologicals"[varies]1952-1960: "An encyclopedia for chemists, pharmacists, physicians, and members of allied professions."Mode of access: Internet.First ed. published in 1889 under title: Merck's index to fine chemicals and drugs for the materia medica and the arts; 2d ed. under title: Merck's 1896 index; 3d ed. under title: Merck's 1907 index; 4th ed. (1930) under title: Merck's index; 6th-7th editions (1952-1960) under title: The Merck index of chemicals and drugs.Sci, Last v. SciRef; C, Rare
Pharmaceutical research in Wilhelmine Germany: The case of E. Merck
No full textIn this paper, we describe the emergence and evolution of pharmaceutical research at the German company E. Merck during the late 19th and early 20th century. Revolutionary changes in the scientific knowledge base, especially the rise of bacteriological research, and the market entry of dyestuff producers into pharmaceuticals made the re-organisation of pharmaceutical research during the 1890s a necessary corporate strategy. Consequently, Merck restructured its in-house research between 1895 and 1898. Moreover, the firm deepened its co-operation with universities and other outside inventors. Jointly and severally, the firm depended on outside inventors for the generation of new products, whereas in-house scientists improved the productive efficiency. Moreover, we show that a significant number of new products were launched between the late 1890s and 1905. During the following years, however, resource constraints restricted Merck’s innovative capacity.Business history, pharmaceutical research, case study
Question XXIX (posée par M. A.-E. C.), Pharmaciens artistes
No full textMerck Augustin. Question XXIX (posée par M. A.-E. C.), Pharmaciens artistes. In: Revue d'histoire de la pharmacie, 48ᵉ année, n°165, 1960. p. 352
Question XXIX (posée par M. A.-E. C.), Pharmaciens artistes
No full textMerck Augustin. Question XXIX (posée par M. A.-E. C.), Pharmaciens artistes. In: Revue d'histoire de la pharmacie, 48ᵉ année, n°165, 1960. p. 352
The Testing of Water : A Selection of Chemical Methods for Practical Use
No full textDarmstadt-, 107 P.: illus.; 20 c
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index
No full textObesity is globally prevalent and highly heritable, but its underlying genetic factors remain largely elusive. To identify genetic loci for obesity susceptibility, we examined associations between body mass index and similar to 2.8 million SNPs in up to 123,865 individuals with targeted follow up of 42 SNPs in up to 125,931 additional individuals. We confirmed 14 known obesity susceptibility loci and identified 18 new loci associated with body mass index (P < 5 x 10(-8)), one of which includes a copy number variant near GPRC5B. Some loci (at MC4R, POMC, SH2B1 and BDNF) map near key hypothalamic regulators of energy balance, and one of these loci is near GIPR, an incretin receptor. Furthermore, genes in other newly associated loci may provide new insights into human body weight regulation
Kiri Fr. C. von Buri`le (?)
No full textMerck, Johann Heinrich, 1741-1791, saksa kirjanik, sõjanõunikBuri, Friedrich Carl von, 1702-1767Finantsprobleemi
Tubulin and microtubules as drug targets for potential cancer chemotherapy and CNS-directed therapies
No full textMicrotubules (MTs) are key components of the cytoskeleton in most eukaryotic cells. One of the distinctive characteristics of MTs is the “dynamic instability” as their assembly is a dynamic process characterized by the continuous transitions between polymerization and depolymerization. Because of their dynamicity, MTs play a significant role in a number of essential cellular functions, such as maintenance of cell shape, cell motility, intracellular transport and cell division. Interfering with the dynamic MT equilibrium prevents proper cellular functions and ultimately leads to cell death. This strategy resulted in a productive approach that has been widely used in different therapeutic areas for the development of efficient drug treatments.
Chapters 2−4 of this thesis describe the three main projects that underpin my research activity in the PhD program:
(a) Drug design and synthesis of 2-phenylindole derivatives as new tubulin polymerization inhibitors and selective colchicine-binding site competitors that showed potent antimitotic activity against multi-drug resistant cell lines. These novel compounds exhibited potential to treat cancer via both MT-based and MT-independent pathways. Moreover, selected examples strongly inhibited the Hedgehog signaling pathway.
(b) Structure-activity relationship (SAR) studies of multitargeted imidazoles as drug candidates for a potential therapeutic approach for Alzheimer’s disease and related neurodegenerative diseases. This study led to the identification of several compounds that exhibit balanced in vitro multitargeted activity as MT-stabilizing agents and/or cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) inhibitors in the low micromolar range. In addition, several of these multitargeted agents were found to be brain-penetrant.
(c) Evaluation of central nervous system (CNS)-active, tubulin polymerization promoters as potential candidate therapeutics for the human African trypanosomiasis and possible other neuroparasitic infections. These studies led to the identification of a promising drug candidate, which combines both in vitro anti-trypanosomal activity and favorable drug-like properties, including brain penetration, metabolic stability and oral bioavailability. Furthermore, SAR studies conducted on a series of MT-stabilizing triazolopyrimidine and phenylpyrimidine analogues led to the identification of several examples that kill Trypanosoma brucei in vitro with IC50 values in the single-digit nanomolar range. Finally, preliminary screening against another CNS-invasive parasite, Naegleria fowleri, revealed that this type of compounds may be of potential use in the context of different parasitic infections.
Chapters 5–7 briefly present other research collaborations, in which I have been involved:
(d) Discovery of 1,1′-biphenyl-4-sulfonamides as potent inhibitors of the human carbonic anhydrase ezymes.
(e) SAR studies of arylboronic acids as dual ligands of fatty acid amide hydrolase (FAAH) enzyme and transient receptor potential vanilloid 1 (TRPV1) channel.
(f) Evaluation of oxetan-3-ol, thietan-3-ol, and derivatives thereof as bioisosteres of the carboxylic acid functional group and dual COX/5-LOX inhibitors
- …
